PRTO - Proteon Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.35
+0.05 (+2.17%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.30
Open2.30
Bid0.75 x 1300
Ask2.45 x 1200
Day's Range2.26 - 2.37
52 Week Range1.30 - 2.90
Volume13,103
Avg. Volume25,639
Market Cap41.658M
Beta1.70
PE Ratio (TTM)N/A
EPS (TTM)-2.02
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.75
Trade prices are not sourced from all markets
  • Associated Press15 days ago

    Proteon Therapeutics: 2Q Earnings Snapshot

    On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 28 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

  • GlobeNewswire15 days ago

    Proteon Therapeutics Announces Second Quarter 2018 Financial Results

    WALTHAM, Mass., Aug. 07, 2018-- Proteon Therapeutics, Inc., a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced ...

  • GlobeNewswire2 months ago

    Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 21st

    WALTHAM, Mass., June 14, 2018-- Proteon Therapeutics, Inc., a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced ...

  • Proteon Therapeutics Inc’s (NASDAQ:PRTO) Earnings Dropped -27.47%, How Did It Fare Against The Industry?
    Simply Wall St.3 months ago

    Proteon Therapeutics Inc’s (NASDAQ:PRTO) Earnings Dropped -27.47%, How Did It Fare Against The Industry?

    Measuring Proteon Therapeutics Inc’s (NASDAQ:PRTO) track record of past performance is a valuable exercise for investors. It allows us to understand whether or not the company has met or exceedRead More...

  • ACCESSWIRE3 months ago

    Blog Exposure - Proteon Extended Long-term Contract with Lonza for Commercial Supply of Vonapanitase's Active Pharmaceutical Ingredient

    LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on Proteon Therapeutics, Inc. (NASDAQ: PRTO), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=PRTO as the Company's latest news hit the wire. On May 8, 2018, the Company announced that it has extended its long-term contract with Lonza Pharma & Biotech for the commercial supply of investigational vonapanitase's active pharmaceutical ingredient (API). Active-Investors.com is currently working on the research report for BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), which also belongs to the Healthcare sector as the Company Proteon Therapeutics.

  • Associated Press3 months ago

    Proteon Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 34 cents. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • Proteon Therapeutics Inc (NASDAQ:PRTO): Are Analysts Optimistic?
    Simply Wall St.5 months ago

    Proteon Therapeutics Inc (NASDAQ:PRTO): Are Analysts Optimistic?

    Proteon Therapeutics Inc’s (NASDAQ:PRTO): Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. The US$39.64MRead More...